Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Another JDRF Partner Moves Research Forward With Collaboration Agreement For Diabetes Treatment
The Juvenile Diabetes Research Foundation said recently that for the fourth time in 18 months, one of its biotech partners has signed a collaboration agreement with a large pharmaceutical company to move research on type 1 diabetes into the final phases of trials.
generic viagra online
Unseen Long-Term Benefits From Cystic Fibrosis Treatments
Cystic fibrosis medicines that help to break down mucus in the lungs may carry an unexpected long-term benefit, a study suggests.
News of the day
Jazz Pharmaceuticals And UCB Announce Second Phase III Study Of Sodium Oxybate In Patients With Fibromyalgia Meets Primary Endpoints
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. Confirming the positive results from the first Phase III study, this international, placebo-controlled trial of sodium oxybate to treat fibromyalgia achieved its key endpoints. As in the first randomized, double-blind fibromyalgia study, sodium oxybate significantly decreased pain and fatigue and improved daily function and patient global impression of change. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use.
Diagnostics

High-Grade Prostate Cancer Outcomes Treated With Combination Of Brachytherapy, External Beam Radiotherapy And Hormonal Therapy

UroToday.com - In the online edition of the BJU International, Dr. Richard Stock and colleagues from Mt. Sinai School of Medicine in New York reported on their outcomes using combined radiotherapy approach to men with high-risk prostate cancer (CaP). The study cohort include 181 men with Gleason score 8-10 CaP treated with androgen deprivation therapy (ADT), brachytherapy, and external beam radiotherapy (ERBT) in combination between 1994 and 2006. The study is non-randomized, single institution and retrospective. The ADT was for 3 months followed by brachytherapy and then 2 months later concomitant ADT and ERBT were delivered. The total ADT duration was 9 months. 103Pd was the isotope for all brachytherapy and most men received a dose of 100Gy with 45Gy ERBT. Median follow-up was 65 months and the Phoenix definition of PSA recurrence was used. The overall 8-year actuarial freedom from biochemical failure was 73%. In 36 patients with a biochemical relapse, the median time to PSA failure was 33 months with 53% failing within 3 years. The median PSADT was 2.7 months. Metastatic CaP developed in 22 patients and the 8-year freedom from distant metastases rate was 80%. The cancer-specific survival and overall survival at 8 years were 87% and 79%, respectively. In men experiencing PSA relapse, the 8-year CSS and overall survival were 53% and 51%, respectively. In multivariable analysis, only Gleason score and initial PSA significantly affected the development of biochemical failure. Toxicity from this treatment approach was not reported. Stock RG, Cesaretti JA, Hall SJ, Stone NN BJU Int. 2009 Jun 2. Epub ahead of print. doi:10.1111/j.1464-410X.2009.08661.x Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009